Home › Research › Tau biomarkers
Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
Grøntvedt GR, Sando SB, Lauridsen C, Bråthen G, White LR, Salvesen Ø, Aarsland D, Hessen E et al.. JAMA network open, 2022-11-01
Topic: Brain proteins, microglia and lab models
Importance Identification of proteins and genetic factors that reduce Alzheimer disease (AD) pathology is of importance when searching for novel AD treatments. Heterozygosity of the KL-VS haplotype has been associated with reduced amyloid and tau burden. Whether this association is mediated by the Klotho protein remains unclear.
Key findings
- Heterozygosity of the KL-VS haplotype has been associated with reduced amyloid and tau burden.
- Whether this association is mediated by the Klotho protein remains unclear.
- Objectives To assess concentrations of Klotho in cerebrospinal fluid (CSF) and plasma among cognitively healthy controls and patients with AD and to correlate these findings with KL-VS heterozygosity status and amyloid and tau burden.
- Design, setting, and participants This case-control study combined 2 independent case-control AD cohorts consisting of 243 referred patients with AD and volunteer controls recruited from January 1, 2009, to December 31, 2018.
Why it matters
This case-control study measured Klotho concentrations in cerebrospinal fluid and plasma and related them to KL-VS heterozygosity and amyloid and tau burden in cognitively healthy controls and patients with Alzheimer disease. It investigates a possible protective factor but does not show that Klotho itself can treat or prevent the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcase-control study
- Participants243
- Effect size38.5%; 57.8%; 50.0%
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal, and it is a case-control study. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA network open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 243 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 27 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 2.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Katja Scheffler: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | King's College London: institution h-index 1,348 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36413367) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2022.43232
- PubMed: 36413367
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Grøntvedt, G. R., Sando, S. B., Lauridsen, C., Bråthen, G., White, L. R., Ø, S., et al. (2022). Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2022.43232
Vancouver
Grøntvedt GR, Sando SB, Lauridsen C, Bråthen G, White LR, Ø S, et al. Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden. JAMA network open. 2022. doi:10.1001/jamanetworkopen.2022.43232. PMID: 36413367.
BibTeX
@article{grontvedt2022-36413367,
author = {Grøntvedt, G. R. and Sando, S. B. and Lauridsen, C. and Bråthen, G. and White, L. R. and Ø, Salvesen and Aarsland, D. and Hessen, E. and others},
title = {{Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden}},
journal = {JAMA network open},
year = {2022},
doi = {10.1001/jamanetworkopen.2022.43232},
pmid = {36413367},
url = {https://doi.org/10.1001/jamanetworkopen.2022.43232}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.